ADC Therapeutics is a clinical-stage oncology biotechnology company engineering next-generation antibody drug conjugates (ADCs) that are not only advancing in clinical trials, but also advancing what's possible in cancer therapy.

ADC THERAPEUTICS
Innovating Science. Inspiring Hope.

adctherapeutics.com

ADC Therapeutics

Moving science forward

ADC Therapeutics is a clinical-stage oncology biotechnology company leading the development and commercialization of next-generation ADCs with highly potent and targeted pyrrolobenzodiazepine (PBD) dimer technology.

our mission We are confronting cancer with the full potential of our science, bringing unique, targeted therapies and hope to patients and their families.

our vision We will transform what patients and their families can expect from cancer therapy.

"At ADC Therapeutics, we believe that science evolves by building and improving on previous discoveries. The progress we've seen in antibody drug conjugates over the past several years is evidence of this. Now, by advancing next-generation ADCs with PBD dimer technology, we're seeing the potential for significant clinical activity in patients with cancer, even those who are often overlooked or who have few therapeutic options. This technology will change the future of patient care, but one thing that will remain the same is our belief that serving those in need is not just a priority. It's a privilege."

CHRIS MARTIN
CHIEF EXECUTIVE OFFICER, CO-FOUNDER, AND DIRECTOR, ADC THERAPEUTICS

ADVANCING from laboratory to IPO

2011

June: ADC Therapeutics founded as a spinoff from Spirogen Ltd, which was founded in 2000 and was an early innovator in PBD-based ADC research

2013

June: Genmab and ADCT enter co-development collaboration for camidanlumab tesirine (Cami)

October: AstraZeneca's MedImmune acquires Spirogen Ltd and makes investment in ADC Therapeutics

2015

June: ADC Therapeutics co-founder, Dr. Chris Martin appointed CEO

2016

February: 1st patient enrolled in Phase 1 clinical trial of Cami in acute myeloid leukemia

March: 1st patient enrolled in Phase 1 clinical trial of loncastuximab tesirine (Lonca) in CD-19 positive B-cell non-Hodgkin lymphoma

2017

June: 1st clinical data presented on the ADC drug candidates Lonca and Cami

2019

October: 1st patient enrolled in Phase 2 clinical trial of Cami in relapsed or refractory Hodgkin lymphoma

2020

March: Ron Squarer, former CEO of Array BioPharma, Inc appointed Chairman of the Board

May: $267 million IPO with the NYSE ticker "ADCT"

June: Announced pivotal Phase 2 clinical trial of Lonca in patients with r/r DLBCL

September: BLA submission for Lonca

ADC THERAPEUTICS

ADVANCING *innovation*

Delivering on the promise of science by advancing

next-generation PBD-based ADCs

ADC Therapeutics is advancing next-generation ADCs with highly potent and targeted PBD dimer technology. These proprietary PBD-based ADCs are expected to provide a novel way to treat hematological cancers and solid tumors, address significant unmet medical needs, and improve the lives of patients with cancer.

1 The antigen-targeted antibody binds to a specific tumor cell surface antigen and internalizes the drug conjugate

2 The potent PBD dimer is released inside the cell, where it then creates a covalent cross-link between the strands of the DNA double helix



3 Because these cross links do not trigger DNA repair, they are invisible to repair mechanisms and can covertly persist to interrupt cell division and cause tumor cell death

ADC THERAPEUTICS

ADVANCING

clinical trials

Lead candidates

LONCASTUXIMAB TESIRINE (Lonca)

In clinical trials, Lonca has demonstrated significant single-agent clinical activity across a broad population of patients with relapsed or refractory diffuse large B-cell, mantle cell, and follicular lymphomas.

THE LOTIS CLINICAL DEVELOPMENT PROGRAM

Lonca is the focus and PBD-based technology is the foundation for the LOTIS Clinical Development Program. Lonca is advancing in clinical trials and demonstrating significant clinical activity across multiple indications.

CAMIDANLUMAB TESIRINE (Cami)

Cami is ADCT's second lead candidate. It has demonstrated significant clinical activity in heavily pretreated patients with Hodgkin lymphoma. Based on its mechanism targeting CD25/regulatory T cells, Cami is also demonstrating potential in the treatment of solid tumors.

The clinical development of Loncastuximab tesirine (ADCT-402) and camidanlumab tesirine (ADCT-301) is ongoing. Lonca and Cami are investigational agents. Safety and efficacy have not yet been established.

ADC THERAPEUTICS

A robust pipeline of ADCs for the treatment of

hematological cancers and solid tumors

ADVANCING clinical trials



*We believe that our Phase 2 clinical trial of Lonca for the treatment of relapsed or refractory DLBCL and our Phase 2 clinical trial of Cami for the treatment of relapsed or refractory Hodgkin lymphoma are pivotal clinical trials (ie, a clinical trial intended to serve as the basis for BLA submission). Therefore, we believe that the Phase 3 clinical trials of Lonca for the treatment of relapsed or refractory DLBCL and of Cami for the treatment of relapsed or refractory Hodgkin lymphoma will be post-marketing confirmatory clinical trials.

†We retain worldwide development and commercialization rights to Cami, subject to our collaboration and license agreement with Genmab.

ADC THERAPEUTICS

ADVANCING

what's possible

innovation

clinical trials

scientific knowledge

For general inquiries, please contact
info@adctherapeutics.com.

For Medical Affairs inquiries, please contact
medicalinformation@ADCTherapeutics.com.

ADC THERAPEUTICS
Innovating Science. Inspiring Hope.

adctherapeutics.com

Stay informed

ADC Therapeutics Head Office | Route de la Corniche 3B, 1066 Epalinges, Switzerland
ADC Therapeutics America | 430 Mountain Avenue, Suite #404. New Providence, NJ 07974, USA